Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics Hires Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality

Marketwired October 14, 2015

Atossa Genetics to Present at Upcoming Investor Conferences

Marketwired October 9, 2015

Atossa Genetics' Laboratory Receives ISO 15189:2012 Certification

Marketwired September 25, 2015

Atossa Genetics Announces FDA Acceptance of Its Investigational New Drug Application to Begin a Phase II Clinical Trial of Fulvestrant for the Treatment of DCIS

Marketwired September 21, 2015

Atossa Genetics Receives Approval to Begin Clinical Study in Israel

Marketwired September 8, 2015

Atossa Genetics Inc. to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

Marketwired September 4, 2015

Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer

Marketwired September 2, 2015

Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update; Achieves Total Revenue for Q2 2015 of $2.7 Million

Marketwired August 6, 2015

Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update; Achieves Total Revenue for Q2 2015 of $2.7 Million

Marketwired August 6, 2015

Atossa Genetics to Announce Second Quarter 2015 Financial Results and Provide a Company Update on Thursday, August 6, 2015

Marketwired August 5, 2015

Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement for Atossa's Lead Drug Candidate Afimoxifene Gel

Marketwired August 5, 2015

Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement for Atossa's Lead Drug Candidate Afimoxifene Gel

Marketwired August 5, 2015

Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTAG Platform

Marketwired July 22, 2015

Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTAG Platform

Marketwired July 22, 2015

Atossa Genetics Announces Acquisition of Ductal Lavage Specimen Bank From the Dr. Susan Love Research Foundation

Marketwired July 1, 2015

Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast Cancer Detection Using Absorbent Paper

Marketwired June 11, 2015

Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors

Marketwired June 5, 2015

Atossa Genetics to Present at the LD Micro Invitational Conference on Tuesday, June 2, 2015

Marketwired May 29, 2015

Atossa Genetics Announces $25 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC

Marketwired May 28, 2015

Atossa Genetics Hires Dr. Gerald Engley as Senior Director of Medical Affairs

Marketwired May 27, 2015